Navigation Links
Macroglobulinemia in Medical News

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...d with chlorambucil in patients with previously untreated CLL. In NHL, an ongoing Phase II study will assess ofatumumab in patients with Waldenstrom's macroglobulinemia - a rare type of slow-growing NHL.(8) Finally, a Phase II study is evaluating ofatumumab plus ICE or DHAP chemotherapy regimen in relapsed/refractory ...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

...ER 6th Abstract 1010 TITLE: Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom macroglobulinemia (WM) Session Name: Biologic Therapies for NHL (Excluding Pre-clinical Models) Presentation Time: 5:30 PM - 7:30 PM Location: Moscone Center, Hall...

Risk of Lymphoma Increases With Hepatitis C Virus Infection

...nd that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20 percent to 30 percent. The risk of developing Waldenstrm's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain ant...
Macroglobulinemia in Medical Technology

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presents phase 2 results demonstrating the single agent clinical activity of perifosine in patients with relapsed / refractory Waldenstroms Macroglobulinemia NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nas...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held in Kos, Greece demonstrates clinical activity of perifosine in combination with bortezomib, dexamethasone and lenalidomide plus dexamethasone, in patients with relapsed/refractory multiple myeloma, and as a single agent in patients with...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...l Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom's macroglobulinemia (WM) Single agent perifosine achieved a 36% ORR (MR, PR) and 58% stable disease in a heavily pre-treated Waldenstrom's macroglobulinemia patient population. Clinical benefit was demonstrated as reflected by a me...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

...Centers-Midtown: Phase II study of oral Panobinostat in adult patients with advanced refractory multiple myeloma Waldenstrom macroglobulinemia Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II trial of combination of Bortezomib and Rituximab in relapsed...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...ferent underlying anemias will also be presented RAD001 data demonstrating benefit in patients with relapsed and/or refractory Waldenstrom macroglobulinemia (ASH Abstract #1011 ; Saturday, December 6, 2008; 5:30 - 7:30 PM PST) More than 10 abstracts on p anobinostat ( LBH589 ), showing e...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

....D., Rocky Mountain Cancer Centers-Rose, and John Mattern, D.O., Virginia Oncology Associates-Newport News: Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180 About US Oncology Research The US Oncology Research netw...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

... Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a NEW YORK, June 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

...established agents in patients with relapsed MCL, indolent NHL and Waldenstrom's Macroglobulinemia, including: -- Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG clinical trial 05-180 -- Lead investigator: Steven Treon, M.D., Ph.D., Assistan...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...7:45am; McCormick Place Convention Center, E Arie Crown Theater Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15pm; McCormick Place Convention Center, E354b Oral Presentation: Impact of prior thalidomide (T...

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

...ace Convention Center, S HallA2 Data Presented Sunday, June 3 Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15 pm; McCormick Place Convention Center, E354b Oral Presentation: Impact of prior thalidomide (...
Macroglobulinemia in Biological News

Risk of lymphoma increases with hepatitis C virus infection

...ne, found that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20 percent to 30 percent. The risk of developing Waldenström's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain ant...
Macroglobulinemia in Biological Technology

The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research

WHITE PLAINS, N.Y., July 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and The International Waldenstrom's Macroglobulinemia Foundation (IWMF) have partnered in an initiative to develop stable and immortalized Waldenstrom's macroglobulinemia (WM) cell lines that would be made widely ...

Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan

...atory studies of perifosine as a treatment for the following tumor types: renal cell, colon, hepatocellular, multiple myeloma, waldenstrom's macroglobulinemia and sarcoma; -- terminating our license agreement for KRX-0601 (UCN-01); and -- closing the Company's San Francisco, California and Memphis, Ten...

Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma

...more information on multiple myeloma go to http://www.cancer.gov/cancertopics/types/myeloma . About Waldenstrom's Macroglobulinemia Waldenstrom's macroglobulinemia (WM) is a slow-growing type of non-Hodgkin's lymphoma that starts in white blood cells called B lymphocytes. WM is also called lymphoplasmacytic lymph...
Other Tags
(Date:7/31/2015)... ... July 31, 2015 , ... India Network Foundation sponsors visitor health ... or family visit for the past 25 years. As India Network offers coverage for ... travel and spend time with their children and grand children. India Network specializes ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... , ... In an effort to provide the twenty four hour continuous care ... his practice. , The decision will also allow him to spend more time in ... his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always ...
(Date:7/30/2015)... ... 2015 , ... Eyepartner is proud to highlight that their ... Gaslamp Quarter Plaza for five years this September. , The surveillance and ... any suspicious activity. These cameras are in place to provide inarguable proof in ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
Other Contents